Eli Lilly has announced that a late-stage trial of its investigative candidate, donanemab, significantly slowed the cognitive and functional decline in people with early symptomatic Alzheimer's disease. …
Lilly's investigative Alzheimer’s treatment slowed disease progression in late-stage trial
May 4, 2023 Latest NewsBioPharma
Latest Video
New Stories
-
Medicines Australia announces appointment of new board chair
March 20, 2025 - - Latest News -
The 'Week in Review Dispatched' Podcast - 21 March
March 20, 2025 - - Podcast -
New NZ approval clears the way for expanded access to cystic fibrosis therapy
March 20, 2025 - - Latest News -
The minister and the US-based industry have a lot in common, including their criticisms of the PBS
March 20, 2025 - - Latest News -
Sigma releases final pre-merger full-year result, confirming impact of CW supply contract
March 20, 2025 - - Latest News -
Stakeholder backing for another PBS co-pay reduction
March 20, 2025 - - Latest News -
If our own government isn't going to do anything, then we can only hope for intervention
March 20, 2025 - - Latest News